emiltatug ledadotin (XMT-1660)

News alerts, weekly reports and conference planners

Company:

Mersana

Drug class:

Tubulin inhibitor, B7-H4-targeted antibody-drug conjugate

Related drugs:

‹

›

No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	XMT-1660 Sensitive: B - Late Trials XMT-1660 Sensitive : B	XMT-1660 Sensitive: B - Late Trials XMT-1660 Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	XMT-1660 Sensitive: D – Preclinical XMT-1660 Sensitive : D	XMT-1660 Sensitive: D – Preclinical XMT-1660 Sensitive : D
VTCN1 expression	Breast Cancer	VTCN1 expression	Breast Cancer	XMT-1660 Sensitive: D – Preclinical XMT-1660 Sensitive : D	XMT-1660 Sensitive: D – Preclinical XMT-1660 Sensitive : D

Associations
(3)